{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T20:48:07Z","timestamp":1757623687494,"version":"3.44.0"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T00:00:00Z","timestamp":1696896000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Exploratory Research in Clinical and Social Pharmacy"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.rcsop.2023.100347","type":"journal-article","created":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T12:01:25Z","timestamp":1697198485000},"page":"100347","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Ticagrelor versus clopidogrel for recurrent myocardial infarction: An outcomes-based agreement"],"prefix":"10.1016","volume":"12","author":[{"given":"Samuel K.","family":"Peasah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Venditto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Brekosky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Belletti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chronis","family":"Manolis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chester B.","family":"Good","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.rcsop.2023.100347_bb0005","first-page":"277","article-title":"Accountability is everything: outcomes-based pharmaceutical agreements","volume":"12","author":"Gonzalez","year":"2019","journal-title":"Am Health Drug Benefits"},{"issue":"9","key":"10.1016\/j.rcsop.2023.100347_bb0010","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s40273-021-01050-5","article-title":"Implementing outcomes-based managed entry agreements for rare disease treatments: nusinersen and tisagenlecleucel","volume":"39","author":"Facey","year":"2021","journal-title":"Pharmacoeconomics."},{"issue":"10","key":"10.1016\/j.rcsop.2023.100347_bb0015","first-page":"1042","article-title":"Performance-based risk-sharing arrangements: US payer experience","volume":"23","author":"Goble","year":"2017","journal-title":"J Manag Care Spec Pharm"},{"issue":"4","key":"10.1016\/j.rcsop.2023.100347_bb0020","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.jval.2020.01.006","article-title":"Is there a future for value-based contracting?","volume":"23","author":"Cohen","year":"2020","journal-title":"Value Health"},{"key":"10.1016\/j.rcsop.2023.100347_bb0025","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jval.2017.07.009","article-title":"Payer and pharmaceutical manufacturer considerations for outcomes-based agreements in the United States","volume":"21","author":"Brown","year":"2018","journal-title":"Value-in-Health"},{"issue":"11","key":"10.1016\/j.rcsop.2023.100347_bb0030","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.rcsop.2023.100347_bb0035","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/s12872-018-0948-4","article-title":"Compared efficacy of clopidogrel and ticagrelor in treating acute coronary syndrome: a meta-analysis","volume":"18","author":"Wang","year":"2018","journal-title":"BMC Cardiovasc Disord"},{"issue":"44","key":"10.1016\/j.rcsop.2023.100347_bb0040","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1093\/eurheartj\/ehw284","article-title":"Outcomes in patients treated with ticagrelor or clopidogrel after acute myocardial infarction: experiences from SWEDEHEART registry","volume":"37","author":"Sahlen","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.rcsop.2023.100347_bb0045","doi-asserted-by":"crossref","first-page":"S275","DOI":"10.37765\/ajmc.2020.88519","article-title":"Translating clinical evidence into value-based payment models: pooled analyses of innovative real-world outcomes agreements for ticagrelor in the United States","volume":"26","author":"Bhandary","year":"2020","journal-title":"Am J of Manag Care"},{"issue":"2","key":"10.1016\/j.rcsop.2023.100347_bb0050","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s40119-021-00236-4","article-title":"Hospitalization for myocardial infarction with ticagrelor or clopidogrel in patients with acute coronary syndrome: an on-treatment comparative effectiveness analysis","volume":"10","author":"Olufade","year":"2021","journal-title":"Cardiol Ther"},{"key":"10.1016\/j.rcsop.2023.100347_bb0055","first-page":"144e","article-title":"ACC\/AHA\/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"2021","author":"Lawton","year":"2021","journal-title":"Circulation."},{"issue":"11","key":"10.1016\/j.rcsop.2023.100347_bb0060","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1007\/s00108-021-01189-5","article-title":"Dual antiplatelet therapy after acute coronary syndrome or percutaneous coronary intervention: with what and for how long?","volume":"62","author":"Darius","year":"2021","journal-title":"Internist (Berl)"},{"issue":"4","key":"10.1016\/j.rcsop.2023.100347_bb0065","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/eurheartj\/ehaa739","volume":"42","author":"Giacoppo","year":"2021","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.rcsop.2023.100347_bb0070","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2147\/CEOR.S51052","article-title":"Cost-effectiveness of ticagrelor versus clopidogrel in patients with acute coronary syndromes in Canada","author":"Grima","year":"2014","journal-title":"Clinicoecon Outcomes Res"},{"issue":"7","key":"10.1016\/j.rcsop.2023.100347_bb0075","doi-asserted-by":"crossref","first-page":"4026","DOI":"10.1007\/s12325-021-01743-5","article-title":"Cost-effectiveness of ticagrelor compared with clopidogrel in patients with acute coronary syndrome from Vietnamese healthcare payers\u2019 perspective","volume":"38","author":"Thi Thu Nguyen","year":"2021","journal-title":"Adv Ther"},{"issue":"2","key":"10.1016\/j.rcsop.2023.100347_bb0080","first-page":"94","article-title":"Cost-effectiveness comparison between ticagrelor and clopidogrel in acute coronary syndrome in Iran","volume":"18","author":"Hashemi-Meshkini","year":"2023","journal-title":"J The Univ Heart Ctr"},{"key":"10.1016\/j.rcsop.2023.100347_bb0085","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1136\/heartjnl-2014-305864","article-title":"Health economic analysis of ticagrelor in patients with acute coronary syndromes intended for non-invasive therapy","volume":"101","author":"Janzon","year":"2015","journal-title":"Heart"}],"container-title":["Exploratory Research in Clinical and Social Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667276623001282?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667276623001282?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T08:32:10Z","timestamp":1757406730000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667276623001282"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":17,"alternative-id":["S2667276623001282"],"URL":"https:\/\/doi.org\/10.1016\/j.rcsop.2023.100347","relation":{},"ISSN":["2667-2766"],"issn-type":[{"type":"print","value":"2667-2766"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ticagrelor versus clopidogrel for recurrent myocardial infarction: An outcomes-based agreement","name":"articletitle","label":"Article Title"},{"value":"Exploratory Research in Clinical and Social Pharmacy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rcsop.2023.100347","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100347"}}